Thursday, September 6, 2012
Researchers at the Dana-Farber Cancer Institute and the Baylor College of Medicine have
shown that Tensha Therapeutics Inc.'s bromodomain inhibitors could prevent sperm
production and be developed as a male contraceptive.1 The biotech,
which is focused on developing the molecules for cancer, has exclusive rights
to the findings and is interested in pursuing bromodomain inhibitors in the
Martz, L. SciBX 5(35); doi:10.1038/scibx.2012.914
Published online Sept. 6, 2012
1. Matzuk, M.M. et al.
Cell; published online Aug. 17, 2012; doi:10.1016/j.cell.2012.06.045
Contact: James E. Bradner, Dana-Farber Cancer Institute,
Contact: Martin M. Matzuk, Baylor College of Medicine,
2. Shang, E. et al.
Development 134, 3507-3515 (2007)
3. Aston, K.I. et al.
Hum. Reprod. 25, 1383-1397 (2010)
AND INSTITUTIONS MENTIONED
Baylor College of Medicine, Houston, Texas
Boston Children's Hospital, Boston, Mass.
Columbia University Medical Center, New York, N.Y.
Dana-Farber Cancer Institute, Boston, Mass.
The George Washington University School of Medicine and
Harbor-UCLA Medical Center, Torrance, Calif.
Harvard Medical School, Boston, Mass.
Los Angeles Biomedical Research Institute, Los Angeles, Calif.
Tensha Therapeutics Inc., Cambridge, Mass.
Texas A&M University, College Station, Texas
The University of North Carolina at Chapel Hill, Chapel Hill, N.C.
University of Oxford, Oxford, U.K.
The University of Utah School of Medicine, Salt Lake City, Utah